Skip to main content
TipRanks
Go Ultimate75% OFF

Hyperion DeFi (HYPD) Drug Pipeline

969 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Tropicamide-Phenylephrine Fixed Combination Ophthalmic SolutionMydriasisPhase IVCompletedEvaluation of Pupil Dilation Speed With the MAP DispenserMay 25, 2021―
Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic SolutionMyopiaPhase IIITerminatedMicrodosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia ProgressionMay 07, 2019―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Hyperion Defi, Inc. (HYPD) have in its pipeline
Hyperion DeFi HYPD is currently developing the following drugs: Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution, Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution. These drug candidates are in various stages of clinical development as the company works toward FDA approval.